Drug intelligence / Profile preview

Exalgo (Mallinckrodt Pharmaceuticals)

Development stage
Unknown
Lead developer
Mallinckrodt
Modality
Small Molecules
Administration
Oral
01

Overview

Exalgo is an extended-release, once-daily oral formulation of hydromorphone hydrochloride, a semi-synthetic opioid analgesic. It utilizes the OROS (Osmotic Release Oral System) delivery technology, which employs osmotic pressure to deliver the drug at a controlled rate through a laser-drilled orifice. This mechanism ensures stable plasma concentrations over a 24-hour period, reducing the "peak-and-trough" effect common with immediate-release formulations. Developed by Mallinckrodt, Exalgo is indicated for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid therapy. Clinical studies have specifically evaluated its efficacy and safety in patients with chronic osteoarthritis pain of the hip or knee.

Brand names
Exalgo
Other names
OROS hydromorphonehydromorphone hydrochloride extended-release
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on Exalgo (Mallinckrodt Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exalgo (Mallinckrodt Pharmaceuticals).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call